

# Streamlining Staging of Lung cancer with Whole Body MRI

<b>Submission date</b> 26/07/2012	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 31/07/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/12/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-mri-scan-diagnose-non-small-cell-lung-cancer-streamline-l>

## Contact information

### Type(s)

Scientific

### Contact name

Prof Stuart Taylor

### Contact details

University College London Hospitals  
Specialist X Ray Department  
235 Euston Road  
London  
United Kingdom  
NW1 2BU

-  
stuart.taylor1@nhs.net

## Additional identifiers

### Protocol serial number

Streamline L

## Study information

### Scientific Title

# Comprehensive staging of newly diagnosed lung cancer: prospective multi-centre comparison of whole body Magnetic Resonance Imaging with standard diagnostic imaging pathways

## Acronym

Streamline L

## Study objectives

To evaluate whether early whole body magnetic resonance imaging (WB-MRI) increases per patient sensitivity for metastasis in lung cancer compared to standard NICE-approved diagnostic pathways.

More details can be found at <http://www.hta.ac.uk/project/2804.asp>

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Camden and Islington Research Ethics Committee, 20/08/2012, ref: 12/LO/1177

## Study design

Multicentre comparison

## Primary study design

Observational

## Study type(s)

Screening

## Health condition(s) or problem(s) studied

Non small cell lung cancer

## Interventions

There are no treatment arms, every patient will receive a whole body MRI as part of the trial which takes about an hour. Aside from attending for the WB-MRI scan, patients shouldn't have to attend for any extra visits. All patients will be asked to complete quality of life forms (EQ-5D) at 0, 3, 6 and 9 months post staging. As part of the health economics portion of the trial, all patients will also be asked to complete patient diaries which will collect information about visits to the GP and hospital and about other medical tests and treatment for a year post staging. As part of the health psychology portion of the trial, 25 patients will take part in an interview (30 minutes) and 75 patients will be given questionnaires complete about their experience of staging at 0, 1, 3, 6, 9, and 12 months post staging. Follow-up CRFs will be completed for a year post-staging but there are no trial specific visits, this data is collected for the health economic portion of trial.

## Intervention Type

Other

## Phase

Not Applicable

### **Primary outcome(s)**

Per patient sensitivity for metastasis detection by whole body MRI (WB-MRI) compared to standard staging pathways in newly diagnosed non small cell lung cancer

### **Key secondary outcome(s)**

1. The time and test number taken to reach, and the nature of, the first major treatment decision based on WB-MRI in comparison to standard staging pathways.
2. Diagnostic accuracy of WB-MRI and conventional staging pathways for local tumour staging and detection of metastasis in comparison to an expert derived consensus reference standard.
3. Lifetime incremental cost and cost-effectiveness of staging using WB-MRI compared to standard diagnostic pathways.
4. Patient experience of staging using WB-MRI in comparison to standard diagnostic pathways and priorities placed by patients on differing attributes related to competing staging pathways.
5. Inter-observer variability in WB-MRI analysis and affect of diagnostic confidence on staging accuracy.
6. Diagnostic accuracy of limited T1 and diffusion weighted sequences compared to full multi-sequence WB-MRI protocols.

### **Completion date**

01/01/2019

## **Eligibility**

### **Key inclusion criteria**

1. Adult patients (18 or over) with histologically proven or clinically diagnosed primary non small cell lung cancer with potentially radically treatable disease
2. Clinically diagnosed non small cell lung cancer defined as radiological diagnosis of lung cancer on chest CT with sufficient confidence to trigger staging investigations
3. Potentially radically treatable disease defined as stage IIIb or less on diagnostic CT (ie T14, N02, M0)
4. Performance status 02 (fit to undergo surgery if indicated)
5. Patient must have given written informed consent and be willing to comply with the protocol intervention and follow up.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Sex**

All

### **Total final enrolment**

### **Key exclusion criteria**

1. Any psychiatric or other disorder likely to impact on informed consent
2. Evidence of severe or uncontrolled systemic disease which make it undesirable the for the patient to participate in the trial
3. Pregnancy
4. Contraindications to MRI (e.g. cardiac pacemaker, severe claustrophobia, inability to lie flat)
5. Unequivocal metastatic or N3 disease on diagnostic CT chest and abdomen (including M1a disease; malignant pleural effusion)
6. Further staging work up not indicated in the opinion of the MDT due to poor performance status or patient choice.
7. Histologies other than non small cell lung cancer

### **Date of first enrolment**

01/10/2012

### **Date of final enrolment**

01/04/2017

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

**University College London Hospitals**

London

United Kingdom

NW1 2BU

## **Sponsor information**

### **Organisation**

University College London (UK)

### **ROR**

<https://ror.org/02jx3x895>

## **Funder(s)**

**Funder type**

Government

## Funder Name

NIHR Health Technology Assessment Programme - HTA (UK) ref: 10/68/01

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2019	14/05/2019	Yes	No
<a href="#">Results article</a>	results against ISRCTN43958015	01/12/2019	20/12/2019	Yes	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes